Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.75 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.75 |
| ▸ | RARA | P10276 | 11/20 | 0.75 |
| ▸ | RARB | P10826 | 11/20 | 0.75 |
| ▸ | RARG | P13631 | 11/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19560666 | 0.87 | RARA (0.82) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotenic Acid SCHEMBL678713 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotenic Acid SCHEMBL29433140 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotenic Acid SCHEMBL29466098 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| SCHEMBL14330777 | 0.86 | CYP3A4 (0.84) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotene SCHEMBL3134 | 0.86 | RARA (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotene SCHEMBL29397163 | 0.86 | RARA (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotene SCHEMBL5747908 | 0.86 | RARA (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| Tazarotene SCHEMBL29512592 | 0.86 | RARA (1.00) | CYP3A4CYP26A1RARARARBRARG | |
| SCHEMBL5482303 | 0.85 | CYP3A4 (0.83) | CYP3A4CYP26A1RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092744-A1 | RETINOID COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATES THEREOF AND APPLICATION THEREOF | RARA, RARB, RARG | CYP3A4 882/4885CYP26A1 77/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.